Cargando…
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the precise consequences of targeting immune cell trafficking for immunoregulatory network functions are only incompletely...
Autores principales: | Lohmann, Lisa, Janoschka, Claudia, Schulte-Mecklenbeck, Andreas, Klinsing, Svenja, Kirstein, Lucienne, Hanning, Uta, Wirth, Timo, Schneider-Hohendorf, Tilman, Schwab, Nicholas, Gross, Catharina C., Eveslage, Maria, Meuth, Sven G., Wiendl, Heinz, Klotz, Luisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052886/ https://www.ncbi.nlm.nih.gov/pubmed/30050529 http://dx.doi.org/10.3389/fimmu.2018.01560 |
Ejemplares similares
-
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015) -
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
por: Janoschka, Claudia, et al.
Publicado: (2022) -
High anti-JCPyV serum titers coincide with high CSF cell counts in
RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020) -
Immune signatures of prodromal multiple sclerosis in monozygotic twins
por: Gerdes, Lisa Ann, et al.
Publicado: (2020) -
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)